November 27, 2024 — Yesterday, Amgen released topline data on their remarkable monthly obesity medicine – MariTide or maridebart cafraglutide. To us, the results are impressive, albeit preliminary. In 52 weeks of study, patients with obesity or overweight lost approximately 20% of their initial body weight and even after a year, they appeared to still be losing weight. For […]
September 12, 2024 — The obesity buzz of the day at EASD annual meeting is clearly amycretin. Amycretin is a new oral medication under study for obesity that activates both GLP-1 and amylin receptors. The excitement came because this is the first public presentation of clinical data on amycretin. This news is impressive on two counts. First, the dosage […]
September 11, 2024 — In every way we look at this study, it is a remarkable milestone. With a randomized, controlled trial, Claudia Fox and colleagues have shown that a GLP-1, liraglutide, is effective for obesity in children as young as six years of age. In this year-long study, children who received liraglutide for obesity reduced their body mass […]
September 6, 2024 — Think about it. Profound change is coming to healthcare and health systems because of the imperative for obesity care at scale. Right now, we are seeing only a faint glimmer of the changes that lie ahead. That’s because the biggest struggles with this change are very basic. Lilly and Novo Nordisk are straining to produce […]
September 4, 2024 — If nothing else, the ESC (European for Cardiology) Congress in London this week made one thing clear – everyone in mainstream medicine is now ready to claim the disease of obesity. Cardiologists all over the world are adopting a view we’ve been espousing here for decades. Obesity is not a lifestyle. Not a behavioral problem. […]
August 20, 2024 — Semaglutide – under the banner of Ozempic – has set a revolution of obesity medicines in motion. Suddenly, all of the huffing and puffing about “treating obesity seriously” and “obesity as a disease” is moot. Facts on the ground are persuading people to re-orient their thinking about obesity faster than essays and advocacy campaigns ever […]
August 1, 2024 — On the theme of “Is there anything GLP-1s can’t do?” a new randomized controlled trial is coming at us from the Alzheimer’s Association International Conference. It showed promising signs that a GLP-1, liraglutide, might slow the progression of Alzheimer’s disease. Liraglutide is used under the brand name Victoza to treat type 2 diabetes. At higher […]
July 19, 2024 — “If we were just to get a fraction [of potential members] to engage in the way that we do things differently with GLP-1s – it’s an insane opportunity for the company.” These words come from the Life Time chain of fitness clubs about the “Miora” wellness clinics they are now putting inside their facilities. It […]
July 18, 2024 — The excitement of the moment we are in for obesity care can make it hard to step back and take a long view. But a new study in the International Journal of Obesity offers a good reminder about the importance of doing just that. Hanna Konttinen and colleagues offer us a good, objective view of […]
July 13, 2024 — Barely seven months ago, business reporters were telling us Pfizer had decided to “drop,” “stop,” “can,” or “pull the plug” on danuglipron – an oral small molecule for obesity. But as we pointed out at the time, they missed the real story. Pfizer was shifting its gears to focus on a once daily form of […]
